Close Menu


The Norwegian molecular diagnostics firm will use the funds to support its new strategy focused on neuroscience-related tests.

DiaGenic has developed quantitative real-time PCR-based blood tests for Alzheimer's disease and breast cancer, but will refocus its business primarily on its neuroscience-related molecular tests as opposed to its oncology tests, a company executive said.

News from TATAA Biocenter's European qPCR symposium in Göteborg, Sweden, included DiaGenic's PCR-based blood test for Alzheimer's disease and breast cancer; an 'ultrafast, ultracheap' portable real-time PCR system from KIST-Europe; high-resolution melting startup Epilabs from the University of Aarhus and Peter MacCallum Cancer Centre; and Helixis' new thermal cycler.

Myconostica's MycAssay Pneumocystis assay, DiaGenic's ADtect

The Spanish firm will distribute DiaGenic's Alzheimer's test in Europe and Latin America.

DiaGenic licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.


Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.